Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.

Giampaolino P, Di Spiezio Sardo A, Mollo A, Raffone A, Travaglino A, Boccellino A, Zizolfi B, Insabato L, Zullo F, De Placido G, Bifulco G.

J Minim Invasive Gynecol. 2019 May - Jun;26(4):648-656. doi: 10.1016/j.jmig.2018.07.001. Epub 2018 Jul 11.

PMID:
30017893
2.

Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.

Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M.

Ann Oncol. 2011 Mar;22(3):643-9. doi: 10.1093/annonc/mdq463. Epub 2010 Sep 28.

PMID:
20876910
3.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004. Epub 2015 Jun 16.

PMID:
26092080
4.

Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update.

Laurelli G, Falcone F, Gallo MS, Scala F, Losito S, Granata V, Cascella M, Greggi S.

Int J Gynecol Cancer. 2016 Nov;26(9):1650-1657.

PMID:
27654262
5.
6.

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, Xie B, Shi Y, Luo X, Zhang H, Chen X.

Gynecol Oncol. 2019 Apr;153(1):55-62. doi: 10.1016/j.ygyno.2019.01.014. Epub 2019 Jan 21.

7.

Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D.

J Gynecol Oncol. 2018 Mar;29(2):e21. doi: 10.3802/jgo.2018.29.e21. Epub 2018 Jan 2.

8.

Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.

Pronin SM, Novikova OV, Andreeva JY, Novikova EG.

Int J Gynecol Cancer. 2015 Jul;25(6):1010-4. doi: 10.1097/IGC.0000000000000467.

PMID:
25950126
9.

Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.

Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ 3rd.

Gynecol Oncol. 2016 Feb;140(2):234-8. doi: 10.1016/j.ygyno.2015.12.010. Epub 2015 Dec 17.

PMID:
26706662
10.

Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.

Hwang JY, Kim DH, Bae HS, Kim ML, Jung YW, Yun BS, Seong SJ, Shin E, Kim MK.

Int J Gynecol Cancer. 2017 May;27(4):738-742. doi: 10.1097/IGC.0000000000000927.

PMID:
28346240
11.

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN.

Obstet Gynecol. 2018 Jan;131(1):109-116. doi: 10.1097/AOG.0000000000002390.

12.

Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.

Nucera G, Mandato VD, Gelli MC, Palomba S, La Sala GB.

Gynecol Endocrinol. 2013 Mar;29(3):219-21. doi: 10.3109/09513590.2012.738726. Epub 2012 Nov 16.

PMID:
23153053
13.

Oral and intrauterine progestogens for atypical endometrial hyperplasia.

Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N.

Cochrane Database Syst Rev. 2018 Dec 4;12:CD009458. doi: 10.1002/14651858.CD009458.pub3.

PMID:
30521671
14.

Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.

Kim MK, Seong SJ, Song T, Kim ML, Yoon BS, Jun HS, Lee GH, Lee YH.

Gynecol Oncol. 2013 Sep;130(3):470-3. doi: 10.1016/j.ygyno.2013.06.035. Epub 2013 Jun 30.

PMID:
23822890
15.

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.

Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S.

J Gynecol Oncol. 2017 Jan;28(1):e2. doi: 10.3802/jgo.2017.28.e2. Epub 2016 Aug 8.

16.

Progestin intrauterine device in an adolescent with grade 2 endometrial cancer.

Brown AJ, Westin SN, Broaddus RR, Schmeler K.

Obstet Gynecol. 2012 Feb;119(2 Pt 2):423-6. doi: 10.1097/AOG.0b013e318234d97c.

17.
19.

Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.

Kim MK, Seong SJ, Kim YS, Song T, Kim ML, Yoon BS, Jun HS, Lee YH.

Am J Obstet Gynecol. 2013 Oct;209(4):358.e1-4. doi: 10.1016/j.ajog.2013.06.031. Epub 2013 Jun 19.

PMID:
23791687
20.

Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.

Wang Y, Yu M, Yang JX, Cao DY, Yuan Z, Zhou HM, Zhang Y, Li L, Shen K, Wu H.

Int J Clin Oncol. 2019 Jun;24(6):712-720. doi: 10.1007/s10147-019-01404-2. Epub 2019 Feb 12.

PMID:
30746595

Supplemental Content

Support Center